Search - tctmd.com

Displaying 941 - 960 of 1004

Sort: Relevancy | Date

Presentation TCT 2013

Lessons Learned from PARTNER 2A and SURTAVI: Device Specificity, Trial Design, Endpoints, and Future Low-risk Studies

Presenter: Jodi Akin

October 30, 2013

Presentation TCT 2013

Case Presentation Introduction: A Low to Intermediate Risk Patient with Symptomatic Aortic Stenosis Who Doesn't Want Surgery

Presenter: Michael Mullen

October 30, 2013

Presentation TCT 2013

Motion: The Envelope for TAVR Should be Expanded to All Candidates for Conventional AVR - For: The Data are Clear (And Common Sense Rules): TAVR is a Lower Risk Option than...

Presenter: Daniel Blackman

October 30, 2013

News Conference News TCT 2013

Two Trials to Assess TAVR in Moderate-Risk Patients

October 30, 2013

Presentation TCT 2013

TCT-110. Lower risk of severe acute kidney injury in transcatheter aortic valve replacement: intracardiac echocardiography lowers radiocontrast medium requirements

Presenter: Thomas Bartel

October 29, 2013

Presentation TCT 2013

Which Aortic Stenosis Patients Are Too Low-Risk for TAVR?

Presenter: Raj Makkar

October 27, 2013

News Daily News

No Long-term Decline in Cognitive Performance After TAVR

Jason Kahn

October 25, 2013

News Daily News

PARTNER: Lung Disease No Barrier to TAVR But Increases Mortality Risk

October 25, 2013

News Daily News

PARTNER: La Enfermedad Pulmonar No es Barrera para la TAVR pero Aumenta el Riesgo de Mortalidad

October 25, 2013

News Daily News

Clinical Inoperability in TAVR Patients Carries Worse Prognosis than Technical Factors

October 23, 2013

News Daily News

‘Obesity Paradox’ Observed in TAVR Patients

Caitlin E. Cox

October 15, 2013

News Daily News

TAVR Patients with Moderate/Severe Mitral Regurgitation Carry Worse Prognosis

October 11, 2013

News Daily News

Meta-analysis: Women Fare Better Than Men After TAVR Despite More Complications

Yael L. Maxwell

September 27, 2013

News Conference News ESC 2013

PARTNER A: TAVR the Optimal Choice for Diabetic Patients at High Risk

Yael L. Maxwell

September 04, 2013

News Conference News ESC 2013

FRANCE 2: Post-TAVR Aortic Regurgitation Doubles Mortality Risk

Caitlin E. Cox

September 02, 2013

News Daily News

For Inoperable Patients, TAVR Carries Benefits but Raises Lifetime Costs

July 25, 2013

News Daily News

Comparison of Therapies in Multivessel CAD Finds Similar LVEF Preservation at 10 Years

L.A. McKeown

July 24, 2013

News Daily News

European TAVR Usage Tied to Economics, Reimbursement

Yael L. Maxwell

July 12, 2013

News Daily News

El Uso de la TAVR en Europa se asocia a la Economía y a los Reembolsos

Yael L. Maxwell

July 12, 2013

News Daily News

Studies Zero in on Baseline Factors That Influence TAVR Outcome

Caitlin E. Cox

July 11, 2013

Advertisement

Lessons Learned from PARTNER 2A and SURTAVI: Device Specificity, Trial Design, Endpoints, and Future Low-risk Studies

Case Presentation Introduction: A Low to Intermediate Risk Patient with Symptomatic Aortic Stenosis Who Doesn't Want Surgery

Motion: The Envelope for TAVR Should be Expanded to All Candidates for Conventional AVR - For: The Data are Clear (And Common Sense Rules): TAVR is a Lower Risk Option than...

Two Trials to Assess TAVR in Moderate-Risk Patients

TCT-110. Lower risk of severe acute kidney injury in transcatheter aortic valve replacement: intracardiac echocardiography lowers radiocontrast medium requirements

Which Aortic Stenosis Patients Are Too Low-Risk for TAVR?

No Long-term Decline in Cognitive Performance After TAVR

PARTNER: Lung Disease No Barrier to TAVR But Increases Mortality Risk

PARTNER: La Enfermedad Pulmonar No es Barrera para la TAVR pero Aumenta el Riesgo de Mortalidad

Clinical Inoperability in TAVR Patients Carries Worse Prognosis than Technical Factors

‘Obesity Paradox’ Observed in TAVR Patients

TAVR Patients with Moderate/Severe Mitral Regurgitation Carry Worse Prognosis

Meta-analysis: Women Fare Better Than Men After TAVR Despite More Complications

PARTNER A: TAVR the Optimal Choice for Diabetic Patients at High Risk

FRANCE 2: Post-TAVR Aortic Regurgitation Doubles Mortality Risk

For Inoperable Patients, TAVR Carries Benefits but Raises Lifetime Costs

Comparison of Therapies in Multivessel CAD Finds Similar LVEF Preservation at 10 Years

European TAVR Usage Tied to Economics, Reimbursement

El Uso de la TAVR en Europa se asocia a la Economía y a los Reembolsos

Studies Zero in on Baseline Factors That Influence TAVR Outcome

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content